Genomic Vision to Enter into Technological Collaboration with AstraZeneca in Oncology
May 23 2017 - 2:00AM
Business Wire
The FiberVision® platform will test the impact
of a WEE1 kinase inhibitor on DNA replication in cancer cells.
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specialized in the development of diagnostic tests (IVD) for the
early detection of cancers and genetic diseases and applications
for life sciences research (LSR), today announced that they have
entered into a technological collaboration with AstraZeneca in the
field of targeting DNA damage response (DDR) for novel anti-cancer
treatments strategy.
Through the use of FiberVision®, the DNA molecular combing
platform of Genomic Vision, AstraZeneca will evaluate the impact of
the WEE1 kinase inhibitor on DNA replication progression in cancer
cells and how the induction of replication stress contributes to
its anti-tumour efficacy in specific cancer genetic
backgrounds.
Molecular combing should allow a comprehensive characterisation
of the different replication stress effects induced by the WEE1
inhibitors. Wider profiling using the platform will also be carried
out to enable mechanistic differentiation between DDR inhibitors
within the AstraZeneca portfolio. The in-depth scientific
understanding of replication stress obtained by the innovative
molecular combing platform could support the development of new
personalised medicine opportunities for DDR inhibitors.
Aaron Bensimon, CEO of Genomic Vision, declared: “This
collaboration agreement on the use of the molecular combing by
AstraZeneca, one of the most innovative companies in the research
of novel anti-cancer agents, represents a strong recognition of our
technology added value. Initially used for the development of
diagnostic tests, molecular combing indeed offers substantial
outlooks to accelerate the selection and optimization process of
high potential therapeutic compounds for the treatment of
cancer.”
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong proprietary technology allowing to
identify genetic abnormalities, GENOMIC VISION stimulates the
R&D productivity of the pharmaceutical companies, the leaders
of the diagnostic industry and the research labs. The Company
develops a robust portfolio of diagnostic tests (breast, ovarian
and colorectal cancers, myopathies) and analysis tools (DNA
replication, biomarkers discovery, gene editing quality control).
Based near Paris, in Bagneux, the Company has approximately 60
employees. GENOMIC VISION is a public listed company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
- ISIN: FR0011799907). For further information, please visit
www.genomicvision.com
Member of CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the “Risk Factors” section in its Document de
Reference filed with the French Autorité des Marchés Financiers
(AMF) on March 28, 2017, under number R.17-009, available on the
web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170522006127/en/
Genomic VisionAaron BensimonCo-founder, Chairman &
CEOTel. : +33 1 49 08 07
50investisseurs@genomicvision.comorMilestonesPress
RelationsBruno ArabianTel. : +33 1 83 62 34
84barabian@milestones.frorNewCapInvestor RelationsDušan
Orešanský / Emmanuel HuynhTel. : +33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024